A novel EPAC1 inhibitor with cardioprotective effects

DESCRIPTION

Chronic activation of cAMP/EPAC signaling leads to cardiac dysfunction inducing pathologic cardiac remodeling, notably ventricular hypertrophy and fibrosis, and promoting cardiac arrhythmia and heart failure development.

A new family of EPAC-1 inhibitors with cardioprotective effects has been identified to treat heart failure due to high blood pressure or a heart attack. These inhibitors showed they reduced cardiac damages following ischemia reperfusion,  they were EPAC-1 isoform selective, and that they showed a good biological tolerance.

APPLICATION
Treatment of heart failure.